#United States #Menlo Park #GRAIL #cancer detection #Precision Oncology

GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

GRAIL, Inc. (Nasdaq: GRAL), a pioneering company in the healthcare sector, is committed to revolutionizing cancer detection. The company will make a significant presentation at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:50 PM ET. This opportunity will highlight GRAIL's innovative approaches in early cancer detection, particularly through advanced technology.

A Deep Dive into GRAIL's Mission

Founded with a mission to detect cancer at stages when it is most curable, GRAIL leverages cutting-edge technology to achieve this goal. The company focuses on utilizing next-generation sequencing (NGS) and machine learning to identify multiple types of cancer, often in their early stages. This is crucial as early detection significantly increases the chances of effective treatment and successful outcomes.

GRAIL's approach rests on a robust foundation of population-scale clinical studies, which gather comprehensive data to enhance accuracy and reliability in cancer diagnosis. Their technology is not just limited to screening; it spans the continuum of care, ensuring that precision oncology—tailoring treatment based on individual patient's needs—is fully supported.

Webcast Access

For those interested in following GRAIL's presentation, it will be available through a live webcast found in the investor relations section of GRAIL's official website, investors.grail.com. This webcast will also be recorded and accessible for 30 days post-event, allowing investors and stakeholders to revisit the insights shared during the conference.

GRAIL's Technological Innovations

GRAIL uses a targeted methylation-based platform capable of detecting cancer through several means, including:

• - Multi-cancer early detection in symptomatic patients.
• - Risk stratification for more personalized monitoring and treatment plans.
• - Minimal residual disease detection, helping doctors understand the potential return of cancer following treatment.
• - Biomarker subtyping that can guide treatment plans specifically suited to individual patients.
• - Monitoring for treatment response and recurrence that ensures patients receive the most appropriate and timely interventions.

The headquarters of GRAIL is located in Menlo Park, California, and the company also has operational bases in Washington, D.C., North Carolina, and the United Kingdom. They are dedicated to alleviating the global burden of cancer and making strides toward this ambition by employing sophisticated technology combined with rigorous research.

GRAIL's Future and Impact

As the healthcare landscape evolves, the significance of companies like GRAIL becomes increasingly clear. With their commitment to early cancer detection, GRAIL is setting a new standard in how healthcare providers approach oncology. Through public forums like the Morgan Stanley Conference, they not only inform but also inspire future innovations in cancer treatment methods. As they prepare for this anticipated presentation, the healthcare community eagerly awaits to see how GRAIL will continue to shape the future of cancer detection and management.

For additional details about GRAIL's ongoing projects and future endeavors, visit their website at grail.com.